A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the clinical effect of CH-1504 at doses of 0.25, 0.5
and 1.0 mg per day in patients with active rheumatoid arthritis by determining the proportion
of patients achieving an American College of Rheumatology (ACR) 20% improvement response.